Literature DB >> 2833735

Comparative physical dependence studies in rats with flupirtine and opiate receptor stimulating analgesics.

B Nickel1, A Aledter.   

Abstract

In physical dependence studies in rats the principle criterion was loss of body weight after withdrawal of the dependence producing drug. Other typical signs of withdrawal were also observed. In contrast to buprenorphine, codeine and tramadol, flupirtine caused no decrease in body weight and no other withdrawal symptoms. Flupirtine does not produce opiate type physical dependence.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2833735

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  5 in total

1.  Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with antinociceptive/antidepressant-like actions in rodents.

Authors:  E Schlicker; U Werner; M Hamon; H Gozlan; B Nickel; I Szelenyi; M Göthert
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

Review 2.  Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states.

Authors:  H A Friedel; A Fitton
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 3.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 4.  Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol.

Authors:  David H Epstein; Kenzie L Preston; Donald R Jasinski
Journal:  Biol Psychol       Date:  2006-02-23       Impact factor: 3.251

5.  Sex- and Dose-Dependent Differences in the Development of an Addiction-Like Phenotype Following Extended-Access Fentanyl Self-Administration.

Authors:  Eleanor Blair Towers; Ben Setaro; Wendy J Lynch
Journal:  Front Pharmacol       Date:  2022-03-17       Impact factor: 5.988
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.